# aEgIS Biologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aegis-biologics

- Industry: Pharmaceuticals
- Headquarters: Suwon-si, South Korea
- Total disclosed funding: $3.4M
- Latest round: Series A (Feb 1, 2020)
- Investors on record: 1

## About

Based in Suwon, South Korea, and founded in 2018, aEgIS Biologics formerly known as Kynogen specializes in the research and development of pharmaceutical treatments and platforms for cancer. In February 2020, aEgIS Biologics raised KRW 4 billion in series A funding led by new investor DAYLI Partners.

The company’s core product, KG-IM-001, is designed to overcome resistance and improve efficacy in treating severe immune disorders. This biologic candidate targets key pathways involved in immune regulation, aiming to provide safer and more effective alternatives to conventional treatments. aEgIS Biologics also engages in R&D for additional therapeutic platforms addressing unmet needs in immunology.

## Funding rounds

- Series A, Feb 1, 2020, $3.4M — DAYLI Partners

## Investors

- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A